Bonesupport Holding

Declaration of Voting Results & Voting Rights Announcements • Mar 28, 2024

CHANGE IN NUMBER OF SHARES AND VOTES IN BONESUPPORT HOLDING AB (PUBL)

BONESUPPORT HOLDING AB (publ), a leading company in orthobiologics for the management of bone injuries, today announced a change in the number of shares and votes.

As per March 28, 2024, the total number of shares in BONESUPPORT HOLDING AB (publ) amounts to 66,686,350, divided into 65,721,195 ordinary shares with one vote per share and 965,155 series C shares with one-tenth of a vote per share, corresponding to a total of 65,817,710.5 votes.

The change in number of shares and votes is due partly to the conversion of 663,745 series C shares, which previously have been issued and repurchased within the context of the Company's incentive programs LTI 2020 and LTI 2021, into ordinary shares during the month of March, partly to a directed issue of 486,840 series C shares and an immediate repurchase of all 486,840 series C shares, and partly to the exercise of 9,375 warrants for subscription of 1,875 ordinary shares within the employee stock options program 2016/2024. The number of ordinary shares has thus increased by 665,620 and the number of series C shares has decreased by 176,905 shares. Following the conversion, issue, and exercise, the number of votes has increased by 647,929.5.

For more information contact:

BONESUPPORT Holding AB Emil Billbäck, CEO +46 (0) 46 286 53 70

Håkan Johansson, CFO +46 (0) 46 286 53 70 ir@bonesupport.com

Cord Communications Charlotte Stjerngren +46 (0) 708 76 87 87 charlotte.stjerngren@cordcom.se www.cordcom.se

This information is information that BONESUPPORT Holding AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2024-03-28 08:00 CET.

Press Release 28 March 2024 08:00:00 CET

About BONESUPPORT™

BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient's own bone and have the capability of eluting drugs. BONESUPPORT's bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver. The company is based in Lund, Sweden, and the net sales amounted to SEK 591 million in 2023. Please visit www.bonesupport. com for more information.

BONESUPPORT and CERAMENT are registered trademarks of BONESUPPORT AB.

Attachments

CHANGE IN NUMBER OF SHARES AND VOTES IN BONESUPPORT HOLDING AB (PUBL)